Market Place
Sourcing Support
Galmed reports results from ARMOR study showing improvements
04 Jan 2023 //
PR NEWSWIRE
Galmed Reports Significant Anti-Fibrotic Effects of Aramchol in Lung Fibrosis
07 Jul 2022 //
PRNEWSWIRE
Galmed Continues to Drive Innovation with 3 New US Patents Granted for Aramchol
11 Jan 2022 //
PRNEWSWIRE
Galmed Provides +ve Data from ARMOR Study; Reports Q3 2021 Financial Results
08 Nov 2021 //
PRNEWSWIRE
Results of Galmed`s Phase 2b ARREST Trial Published in Nature Medicine
11 Oct 2021 //
PRNEWSWIRE
MHRA Agrees with Galmed`s Plan to use Aramchol meglumine in Phase 3 ARMOR study
16 Aug 2021 //
PR NEWSWIRE
Galmed Announces Successful Completion of End of Ph2 Meeting With FDA
09 Apr 2019 //
BUSINESSWIRE
Copyright © 2024 LePro PharmaCompass OPC Private Limited, All rights reserved.